Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares OutstandingShares Repurchased
Ratios

Dolby Laboratories (DLB) EBIAT (2016 - 2025)

Dolby Laboratories' EBIAT history spans 17 years, with the latest figure at $53.3 million for Q4 2025.

  • For Q4 2025, EBIAT fell 21.37% year-over-year to $53.3 million; the TTM value through Dec 2025 reached $241.0 million, down 8.38%, while the annual FY2025 figure was $255.0 million, 2.6% down from the prior year.
  • EBIAT reached $53.3 million in Q4 2025 per DLB's latest filing, up from $49.3 million in the prior quarter.
  • In the past five years, EBIAT ranged from a high of $98.2 million in Q1 2024 to a low of $9.9 million in Q3 2023.
  • Average EBIAT over 5 years is $57.0 million, with a median of $53.9 million recorded in 2021.
  • Peak YoY movement for EBIAT: tumbled 64.06% in 2023, then soared 491.14% in 2024.
  • A 5-year view of EBIAT shows it stood at $80.0 million in 2021, then decreased by 0.8% to $79.4 million in 2022, then dropped by 14.86% to $67.6 million in 2023, then rose by 0.36% to $67.8 million in 2024, then fell by 21.37% to $53.3 million in 2025.
  • Per Business Quant, the three most recent readings for DLB's EBIAT are $53.3 million (Q4 2025), $49.3 million (Q3 2025), and $46.5 million (Q2 2025).